New pill for advanced prostate cancer shows early promise, but trial halted
NCT ID NCT03843918
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested an oral drug called LAE001 in 33 men with metastatic prostate cancer that had stopped responding to standard hormone therapy. The goal was to check safety and find the right dose, and to see if the drug could lower PSA levels. The trial was terminated early, so we have limited information on how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LAE001 (also known as CFG920), an oral drug
What this could lead to
If successful, this could point toward a new oral treatment option for metastatic prostate cancer that has stopped responding to hormone therapy.
What could go wrong
The trial was terminated early, so results are limited. It was a small, early-phase study (Phase I/II) focused on safety and dosing, not proof of effectiveness. The drug may not work or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan Cancer Hospital
Shanghai, Shanghai Municipality, China
-
ZheJiang Cancer Hospital
Hangzhou, Zhejiang, China